Abstract:Purpose Glucophage R (Merck Healthcare KGaA, Darmstadt, Germany) is the originator brand of metformin hydrochloride, an oral antidiabetic drug. Metformin is recommended in guidelines as first-line treatment of type 2 diabetes mellitus and increasingly in related insulin-resistant conditions, such as prediabetes and polycystic ovary syndrome. The GelShield R sustained-release formulation tablet of Glucophage R has been improved from the historic version marketed in 2000. Bioequivalence has been demonstrated stepwise along this evolution; however, a head-to-head evaluation between the initial and the current version is missing. This analysis aims to close this gap and to determine bioequivalence between related originator GelShield R sustained-release formulations of metformin, Glucophage R (GXR 500 mg), from Europe and the United States. Methods Data from seven randomized crossover bioequivalence studies in 361 healthy participants of Asian and non-Asian ethnicity from Europe, the United States, and Asia were considered. All evaluated a single oral dose of 500 mg of the test and reference formulation in healthy male and female participants in fed and fasted state. Bioequivalence was evaluated by means of a combined bridging analysis of available data on the current round tablet from Europe (rGXR EU) and the historic oblong tablet from the United States (oGXR US) in healthy Asian and non-Asian participants under fed and fasting conditions. Bioequivalence between the two formulations was assessed statistically with a mixed effects model for AUC 0-t , C max , and AUC 0-inf . Findings In all studies, bioequivalence between the respective test and reference formulations of GXR was shown. Statistical analysis of pooled pharmacokinetic data of 2 (primary pooling set) or 3 studies (secondary pooling set) demonstrated bioequivalence between rGXR EU and oGXR US via bridging with oGXR EU. The 90% CI for the geometric mean ratio of all pharmacokinetic parameters was within the bioequivalence range of 0.80 to 1.25. In the primary pooling set, geometric least squares mean ratios in the fed group ranged from 0.9931 (90% CI, 0.9151–1.0778) for AUC 0-inf to 1.1344 (90% CI, 1.0711–1.2014) for C max ; results in the fasted group were similar. The secondary pooling set, which added a study in Asians, confirmed these findings. Implications Bioequivalence was determined between sustained-release formulations of Glucophage R from Europe and the United States under fasted and fed conditions in healthy men and women, including different ethnicities. The efficacy and safety of Glucophage R XR can be claimed along the evolution from oGXR US, via oGXR EU to rGXR EU, and in several ethnicities and production sites.

In–vitro Bioequivalence Study Between four Different Marketed Formulations of Gliclazide with Sustained Release Metformin Hydrochloride Tablet as an Anti-Diabetic Drug

Quality Evaluation of Generic Products of Metformin and Vildagliptin Tablets

Post-Marketing Reevaluation on Bioequivalence of Metformin Hydrochloride Tablets

A comparative study on vildagliptin brand and its generic equivalents using dissolution test as quality control measure tool

Bioequivalence of Related GelShield R Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis

The Bioequivalence Study of Domestic and Imported Gliclazide Sustained Release Tablets

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach

Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin-Metformin Fixed-Dose Combination Compared with the Originator Products

Post-Marketing Reevaluation of Bioequivalénce of Metformin Hydrochloride Enteric-Coated Tablets

Bioequivalence of Gliclazide Sustained Release Tablets

Study of the Bioequivalence of Gliclazide in Chinese Healthy Volunteers

In Vitro and in Vivo Evaluation of Two Extended Release Preparations of Combination Metformin and Glipizide.

Study of bioequivalence of compound metformin hydrochloride tablet in healthy volunteers

An In Vitro–In Vivo Simulation Approach for the Prediction of Bioequivalence

Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Bioequivalence of glipizide orally disintegrating tablets in healthy volunteers

Invitro evaluation of generic vs branded product of metformin tablet

Comparison of release rates of gliclazide sustained- release tablets from different manufactures in different dissolution mediums

Bioequivalence and Safety Assessment of 2 Formulations of Low‐Dose Metformin Hydrochloride under Fasting Conditions in Healthy Chinese Participants: A Randomized Phase I Clinical Trial

Pharmacokinetics and Comparative Bioavailability of Two Metformin Formulations after Single-Dose Administration in Healthy Subjects

Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects